FDA OKs New Therapy for Some Hemophilia Patients - NBC New York
National & International News
The day’s top national and international news

FDA OKs New Therapy for Some Hemophilia Patients

Genentech, the drug's developer, says the list price will be about $482,000 for the first year and slightly less after that

    processing...

    NEWSLETTERS

    FDA OKs New Therapy for Some Hemophilia Patients
    AP/Genentech, Inc.
    This photo provided by Genentech, Inc. shows a package of the drug Hemlibra. On Thursday, Nov. 16, 2017, the Food and Drug Administration approved Hemlibra, the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia, an inherited blood-clotting disorder.

    U.S. regulators have approved the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia, an inherited blood-clotting disorder.

    The Food and Drug Administration on Thursday approved Hemlibra (hem-LEE'-bruh), a weekly injection for hemophilia A patients who have developed resistance to standard medicines.

    Genentech, the drug's developer, says the list price will be about $482,000 for the first year and slightly less after that.

    Genentech, a subsidiary of Swiss drugmaker Roche, says that's half the cost of the only other option for patients with this resistance. That treatment requires an IV drip several times a week.

    Total Lunar Eclipse Comes with Supermoon Bonus

    [NATL] Total Lunar Eclipse Comes with Supermoon Bonus

    On Sunday night, the moon, Earth and sun lined up to create an eclipse, which was visible throughout North and South America, where skies were clear. It was also the year's first supermoon, when a full moon appears a little bigger and brighter. (This video does not have audio)

    (Published Monday, Jan. 21, 2019)

    Hemophilia mostly affects males.